A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
Yamin Shu,Xucheng He,Yanxin Liu,Pan Wu,Qilin Zhang
DOI: https://doi.org/10.2147/CLEP.S365513
2022-06-28
Clinical Epidemiology
Abstract:Yamin Shu, 1 Xucheng He, 2 Yanxin Liu, 3 Pan Wu, 4 Qilin Zhang 5 1 Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 2 Department of Pharmacy, Pengzhou Second People's Hospital, Pengzhou, People's Republic of China; 3 Department of Pharmacy, Pengzhou People's Hospital, Pengzhou, People's Republic of China; 4 Department of Pharmacy, Qionglai Maternal & Child Health and Family Planning Service Center, Qionglai, People's Republic of China; 5 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China Correspondence: Qilin Zhang, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China, Tel +86-02785726073, Email Background: Olaparib, the world's first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA. The current study was to assess olaparib-related adverse events (AEs) of real-world through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of olaparib-associated AEs. Results: Out of 8,450,009 reports collected from the FAERS database, 6402 reports of olaparib-associated AEs were identified. A total of 118 significant disproportionality preferred terms (PTs) conforming to the four algorithms simultaneously were retained. The most common AEs included anemia, thrombocytopenia, nausea, decreased appetite, blood creatinine increased and dermatomyositis, which were corresponding to those reported in the specification and clinical trials. Unexpected significant AEs as interstitial lung disease, Pneumocystis jirovecii pneumonia, folate deficiency, renal impairment and intestinal obstruction might also occur. The median onset time of olaparib-related AEs was 61 days (interquartile range [IQR] 14– 182 days), and most of the cases occurred within the first 1 month after olaparib initiation. Conclusion: Results of our study were consistent with clinical observations, and we also found potential new and unexpected AEs signals for olaparib, suggesting prospective clinical studies were needed to confirm these results and illustrate their relationship. Our results could provide valuable evidence for further safety studies of olaparib. Keywords: olaparib, PARP inhibitor, pharmacovigilance, data mining, FAERS Ovarian cancer is the most lethal of the gynecologic malignancies with a 5-year survival rate of about 47.4%, and approximately 70% have a relapse within the subsequent 3 years. 1–3 Because poly ADP-ribose polymerase (PARP) inhibitors (PARPis) significantly prolonged the progression-free survival (PFS) in patients with ovarian cancer and had a relatively low incidence of serious side effects, they had become an effective treatment option for patients with both primary and recurrent ovarian cancer, which had transformed the oncology landscape. BRCA1/2 gene is a tumor suppressor gene, which plays an important role in DNA damage repair and cell growth. 4,5 Mutations in BRCA genes can inhibit normal DNA repair and cause homologous recombination deficiency (HRD), so that the double strand broken DNA cannot carry out homologous recombination repair, thus resulting in carcinogenesis. Studies have reported that carriers of a pathogenic BRCA1 variant have an estimated 48.3% (95% CI, 38.8–57.9%) cumulative risk of ovarian cancer by age 70, whereas the cumulative risk by age 70 is 20.0% (95% CI, 13.3–29.0%) for carriers of a pathogenic BRCA2 variant. 6 In homologous recombination-deficient tumors, PARPi eliminates an alternative DNA repair pathway essential for maintaining viability, thus forming a "synthetic lethal" effect and finally leading to tumor cells' death. 7 As the first PARPi, olaparib has been widely used in clinic and updated continuously by oncology societies and guidelines to treat ovarian, prostate, breast and pancreatic cancers. 3,8–11 According to the product description and early evaluation of post-marketing safety, the most common adverse drug reactions (ADRs) of olaparib were anemia, thrombocytopenia, neutropenia, leucopenia, fatigue an -Abstract Truncated-
public, environmental & occupational health